Brexpiprazole

Brexpiprazole with CAS# 913611-97-9 , sold under the brand name Rexulti among others, is a medication used for the treatment of major depressive disorder, schizophrenia, and agitation associated with dementia due to Alzheimer’s disease. It is an atypical antipsychotic.

Brexpiprazole was developed by Otsuka and Lundbeck, and is considered to be a successor to aripiprazole (Abilify).It was approved for medical use in the United States^. Brexpiprazole is the first treatment approved by the US (FDA) for agitation associated with dementia due to Alzheimer’s disease

CTX Lifesciences, is one of the leading Active Pharmaceutical Ingredients (API) manufacturers and suppliers globally for Brexpiprazole with CAS# 913611-97-9. We are a leading exporter of Brexpiprazole with CAS# 913611-97-9. We are a trusted supplier with API exports in more than 87 Countries including the US, Europe, Brazil, Latin America,  China, Korea,Iran, Middle East and other emerging markets.

CTX Lifesciences is one of the leading manufacturer & supplier of Brexpiprazole with CAS# 913611-97-9. This product is provided from our GMP compliant plant with product made under complete cGMP conditions. We provided with documentation support Drug Master File(DMF). Our manufacturing plant at Surat has accreditation by US-FDA, EDQM , EMA , ANVISA, KFDA, MOH IRAN, Health Canada & Russian Authorities.